Teva Pharmaceutical Industries Limited (TEVA)
NYSE: TEVA · IEX Real-Time Price · USD
16.81
+0.47 (2.88%)
At close: Jul 19, 2024, 4:00 PM
16.71
-0.10 (-0.59%)
Pre-market: Jul 22, 2024, 7:06 AM EDT
Teva Pharmaceutical Employees
Teva Pharmaceutical Industries had 37,851 employees as of December 31, 2023. The number of employees increased by 1,025 or 2.78% compared to the previous year.
Employees
37,851
Change (1Y)
1,025
Growth (1Y)
2.78%
Revenue / Employee
$422,816
Profits / Employee
-$13,025
Market Cap
19.04B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 37,851 | 1,025 | 2.78% |
Dec 31, 2022 | 36,826 | -711 | -1.89% |
Dec 31, 2021 | 37,537 | -2,679 | -6.66% |
Dec 31, 2020 | 40,216 | 177 | 0.44% |
Dec 31, 2019 | 40,039 | -2,496 | -5.87% |
Dec 31, 2018 | 42,535 | -9,257 | -17.87% |
Dec 31, 2017 | 51,792 | -5,168 | -9.07% |
Dec 31, 2016 | 56,960 | 14,072 | 32.81% |
Dec 31, 2015 | 42,888 | -121 | -0.28% |
Dec 31, 2014 | 43,009 | -1,936 | -4.31% |
Dec 31, 2013 | 44,945 | -1,003 | -2.18% |
Dec 31, 2012 | 45,948 | 194 | 0.42% |
Dec 31, 2011 | 45,754 | 6,094 | 15.37% |
Dec 31, 2010 | 39,660 | 4,571 | 13.03% |
Dec 31, 2009 | 35,089 | -3,218 | -8.40% |
Dec 31, 2008 | 38,307 | 10,395 | 37.24% |
Dec 31, 2007 | 27,912 | 1,242 | 4.66% |
Dec 31, 2006 | 26,670 | 11,972 | 81.45% |
Dec 31, 2005 | 14,698 | 885 | 6.41% |
Dec 31, 2004 | 13,813 | 2,853 | 26.03% |
Dec 31, 2003 | 10,960 | 1,383 | 14.44% |
Dec 31, 2002 | 9,577 | 591 | 6.58% |
Dec 31, 2001 | 8,986 | 361 | 4.19% |
Dec 31, 2000 | 8,625 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Cardinal Health | 48,000 |
Align Technology | 21,610 |
STERIS | 18,179 |
Zimmer Biomet Holdings | 18,000 |
The Cooper Companies | 15,000 |
Illumina | 13,360 |
West Pharmaceutical Services | 10,600 |
Hologic | 6,990 |
TEVA News
- 3 days ago - Teva Announces First Phase 3 Evidence of Efficacy and Safety of an Anti-CGRP Monoclonal Antibody in Children in AJOVY® (fremanezumab) SPACE Trial for Prevention of Episodic Migraine - Business Wire
- 19 days ago - Teva to Host Conference Call to Discuss Second Quarter 2024 Financial Results at 8 a.m. ET on July 31, 2024 - Business Wire
- 20 days ago - Teva's stock falls after report FTC has opened probe of patents - Market Watch
- 20 days ago - FTC starts probe into Teva about some products' patents, Washington Post reports - Reuters
- 23 days ago - New AJOVY® (fremanezumab) Migraine Prevention Data Challenges Treatment Pauses - Business Wire
- 26 days ago - Teva settles tax dispute in Israel with $750 mln payment - Reuters
- 26 days ago - Teva Reaches Agreement With the Israel Tax Authority to Resolve All Pending Litigation for the Company's Taxable Years 2008-2020 - Business Wire
- 27 days ago - Teva launches generic version of Novo Nordisk's diabetes drug Victoza - Reuters